Context Prostate-specific membrane antigen positron emission tomography (PSMA-PET)
has gained acceptance as a staging tool for prostate cancer (PCa). Recent reports suggest …

PET/CT molecular imaging has been imposed in clinical oncological practice over the past
20 years, driven by its two well-grounded foundations: quantification and radiolabeled …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

Multiparametric MRI (mpMRI) is validated for the diagnosis of clinically significant prostate
cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has …

Abstract Preamble The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an
international scientific and professional organization founded in 1954 to promote the …

Approaches and techniques used for diagnostic prostate biopsy have undergone
considerable evolution over the past few decades: from the original finger-guided …

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in
the majority of prostate cancer (PCa). PSMA has an enzymatic function that makes metabolic …

Background/Aim: To evaluate the diagnostic accuracy of 68Ga-prostate-specific membrane
antigen (PSMA) positron emission tomography/computed tomography (PET/CT) vs …

Materials and methods: From January 2021 to June 2022, 100 patients (median age: 66
years) with negative digital rectal examination underwent transperineal prostate biopsy for …

Objective To assess whether a diagnostic pathway in which prostate‐specific membrane
antigen (PSMA) positron‐emission tomography (PET)/computed tomography (CT) is used as …